Abstract Details

Title Characterizing Disability and MRI Outcomes in Latinx People with Multiple Sclerosis Before and After the COVID-19 Pandemic

Topic Multiple Sclerosis

Presentation(s) P4 - Poster Session 4 (5:00 PM-6:00 PM)

Poster/Presentation
Number 1-006

Objective To assess the impact of the COVID-19 pandemic on disability and MRI activity in US Latinx people with multiple sclerosis (PwMS) and how that impact differed from other racial/ethnic groups.

Background

COVID-19 was disruptive for PwMS and more severely impacted US racial/ethnic minorities.

Design/Methods Analysis included PwMS who self-identified as Latinx, Non-Hispanic Black (NHB), or Non-Hispanic White (NHW) in the Multiple Sclerosis Partners Advancing Technology and Health Solutions US sites with ≥1 visit within 1 year prior to March 2020 (pre-COVID), between March 2020-February 2021 (during COVID), and between March 2021-February 2022 (post-COVID [peak]). Performance outcomes included Patient Determined Disease Steps (PDDS), Walking Speed Test (WST), Manual Dexterity Test (MDT), and Processing Speed Test (PST). MRI activity was defined as new T2/gadolinium enhancing (GdE) lesions. Linear mixed-effects models assessed the impact of the periods on disability and MRI measures in Latinx PwMS, adjusting for age, disease duration, MS phenotype, and smoking status. The same models were applied across all groups, adjusting for race. Outcomes were compared between racial/ethnic groups.

Results There were 589 Latinx, 1,422 NHB, and 8,446 NHW PwMS in the study. Baseline characteristics in Latinx, NHB, and NHW were, respectively: female- 75%, 80%, 73%; median [IQR] age of diagnosis- 31 [24-39], 34 [27-42], 36 [29-44] years; relapsing-remitting- 40%, 37%, 42%; current smoker- 13%, 14%, 16%. In Latinx PwMS, MDT (dominant) worsened post-pandemic (p<0.001); PST worsened during the pandemic (p=0.02); WST worsened post-pandemic (p=0.03) compared to the pre-pandemic period. Latinx PwMS had worse MDT, WST, and PST vs NHW (all p<0.001) and better performance measures vs NHB (MDT and WST, p<0.001; PST, p=0.02). There was no significant worsening in PDDS or MRI activity in Latinx PwMS across time periods.

Conclusions Latinx PwMS had worsened disability measures over the pre- to post-pandemic period and demonstrated greater disability worsening than NHW but less than NHB.

Authors/Disclosures
Carrie M. Hersh, DO, MSc, FAAN (Cleveland Clinic Lou Ruvo Center for Brain Health) PRESENTER	Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech_GN41791. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb . Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon Therapeutics. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Hersh has received research support from Biogen. The institution of Dr. Hersh has received research support from Novartis. The institution of Dr. Hersh has received research support from Genentech_GN41791. The institution of Dr. Hersh has received research support from PCORI. The institution of Dr. Hersh has received research support from Bristol Myers Squibb.
Mengke Du (Cleveland Clinic)	Mengke Du has nothing to disclose.
Sarah Worley, MS	Ms. Worley has nothing to disclose.
Daniel Ontaneda, MD, PhD, FAAN (Cleveland Clinic)	Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech/Roche. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Idec. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. The institution of Dr. Ontaneda has received research support from NIH. The institution of Dr. Ontaneda has received research support from PCORI. The institution of Dr. Ontaneda has received research support from NMSS. The institution of Dr. Ontaneda has received research support from Genetech.
Farren Briggs, PhD (University of Miami Miller School of Medicine)	The institution of Prof. Briggs has received research support from NIH.
Devon Conway, MD	Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Conway has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Conway has received research support from Novartis. The institution of Dr. Conway has received research support from BMS. The institution of Dr. Conway has received research support from Biogen.

��ɫ��

��ɫ��